Cannell & Spears LLC Has $4.03 Million Stake in IDEXX Laboratories, Inc. $IDXX

Cannell & Spears LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,176 shares of the company’s stock after selling 1,900 shares during the quarter. Cannell & Spears LLC’s holdings in IDEXX Laboratories were worth $4,026,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Empowered Funds LLC raised its position in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories during the second quarter worth $265,000. Jump Financial LLC boosted its holdings in shares of IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $164,000. Finally, Sei Investments Co. boosted its holdings in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $544.32 on Friday. The business’s 50-day moving average price is $556.27 and its 200-day moving average price is $595.41. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The firm has a market capitalization of $42.94 billion, a price-to-earnings ratio of 40.08, a PEG ratio of 2.98 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the business posted $2.91 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.